These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 2944369)
41. Short-term effects of oral enoximone on hemodynamics, exercise capacity, anaerobic threshold, and arrhythmias in congestive heart failure. Klauss V; Zwehl W; Mudra H; Huber R; Schmidt R; Scheininger M; Vogler A; Tschaidse O; Dieterich HA; Theisen K Klin Wochenschr; 1991 Jul; 69(10):430-5. PubMed ID: 1719270 [TBL] [Abstract][Full Text] [Related]
42. [Comparison of the hemodynamic effects of dobutamine and enoximone in the treatment of low cardiac output after valvular surgery]. George M; Atallah G; Lehot JJ; Bastien O; Durand PG; Estanove S Arch Mal Coeur Vaiss; 1990 Sep; 83 Spec No 3():57-62. PubMed ID: 2147836 [TBL] [Abstract][Full Text] [Related]
43. Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure. Shakar SF; Abraham WT; Gilbert EM; Robertson AD; Lowes BD; Zisman LS; Ferguson DA; Bristow MR J Am Coll Cardiol; 1998 May; 31(6):1336-40. PubMed ID: 9581729 [TBL] [Abstract][Full Text] [Related]
44. Addition of enoximone to adrenergic agents in the management of severe heart failure. Vincent JL; Léon M; Berré J; Mélot C; Kahn RJ Crit Care Med; 1992 Aug; 20(8):1102-6. PubMed ID: 1386567 [TBL] [Abstract][Full Text] [Related]
45. A double-blind dose response comparison of oral enoximone and placebo for congestive heart failure. Zipperle G; Butzer F; Dieterich HA; Heinrich F Am J Cardiol; 1987 Aug; 60(5):72C-74C. PubMed ID: 2956873 [TBL] [Abstract][Full Text] [Related]
46. Oral enoximone therapy in chronic heart failure: a placebo-controlled randomized trial. The Western Enoximone Study Group. Narahara KA Am Heart J; 1991 May; 121(5):1471-9. PubMed ID: 1826806 [TBL] [Abstract][Full Text] [Related]
47. Acute effects of enoximone in chronic heart failure. Saborowski F; Peters P; Schneider M; Fehske W; Dieterich HA J Cardiovasc Pharmacol; 1989; 14 Suppl 1():S57-61. PubMed ID: 2480487 [TBL] [Abstract][Full Text] [Related]
50. Rationale and design of the enoximone clinical trials program. Lowes BD; Shakar SF; Metra M; Feldman AM; Eichhorn E; Freytag JW; Gerber MJ; Liard JF; Hartman C; Gorczynski R; Evans G; Linseman JV; Stewart J; Robertson AD; Roecker EB; Demets DL; Bristow MR J Card Fail; 2005 Dec; 11(9):659-69. PubMed ID: 16360960 [TBL] [Abstract][Full Text] [Related]
51. Non-glycoside, non-catecholamine inotropic agents in the treatment of congestive heart failure. Tommaso CL Am J Med; 1986 Feb; 80(2B):36-9. PubMed ID: 3004210 [No Abstract] [Full Text] [Related]
52. Oral treatment with enoximone in patients referred for cardiac transplantation. Coghlan JG; Norell M; Ilsley CD; Mitchell AG Int J Cardiol; 1991 Jul; 32(1):57-63. PubMed ID: 1830866 [TBL] [Abstract][Full Text] [Related]
53. Double-blind placebo-controlled comparison of enoximone and dobutamine infusions in patients with moderate to severe chronic heart failure. Bader FM; Gilbert EM; Mehta NA; Bristow MR Congest Heart Fail; 2010; 16(6):265-70. PubMed ID: 21091611 [TBL] [Abstract][Full Text] [Related]
54. A preliminary report of the effects of orally administered enoximone on regional hemodynamics in congestive heart failure. Leier CV; Meiler SE; Matthews S; Unverferth DV Am J Cardiol; 1987 Aug; 60(5):27C-30C. PubMed ID: 2956864 [TBL] [Abstract][Full Text] [Related]
55. Inotropic therapy for refractory congestive heart failure with oral fenoximone (MDL-17,043): poor long-term results despite early hemodynamic and clinical improvement. Shah PK; Amin DK; Hulse S; Shellock F; Swan HJ Circulation; 1985 Feb; 71(2):326-31. PubMed ID: 3155500 [TBL] [Abstract][Full Text] [Related]
56. [Enoximone in postoperative "low-output syndrome"--comparison with dobutamine]. Orellano L; Darwisch M; Dieterich HA; Köllner V Z Kardiol; 1991; 80 Suppl 4():53-7. PubMed ID: 1833898 [TBL] [Abstract][Full Text] [Related]
57. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group. Uretsky BF; Jessup M; Konstam MA; Dec GW; Leier CV; Benotti J; Murali S; Herrmann HC; Sandberg JA Circulation; 1990 Sep; 82(3):774-80. PubMed ID: 2144216 [TBL] [Abstract][Full Text] [Related]
58. The acute hemodynamic effects of a new agent, MDL 17,043, in the treatment of congestive heart failure. Uretsky BF; Generalovich T; Reddy PS; Spangenberg RB; Follansbee WP Circulation; 1983 Apr; 67(4):823-8. PubMed ID: 6218939 [TBL] [Abstract][Full Text] [Related]
59. Oral enoximone as a substitute for intravenous catecholamine support in end-stage congestive heart failure. Jondeau G; Dubourg O; Delorme G; Arnal JF; Chikli F; Kamoun L; Dumas C; Bourdarias JP Eur Heart J; 1994 Feb; 15(2):242-6. PubMed ID: 8005127 [TBL] [Abstract][Full Text] [Related]